Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
QGEN Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Qiagen N.V.NYSE: QGEN
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of $8.47M (cash outflow) fell 69.7% year over year, behind the +18.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 98.3% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.
Context
- Financing cash flow amounted to 8.6% of revenue in FY2025, down 12.8 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -69.7% toward the trailing-twelve-month pace of +18.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (178.98M) USD
- Year-over-year change
- +57.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (178.98M) | +57.7% |
| FY2024 | 2024-12-31 | (422.9M) | +2.5% |
| FY2023 | 2023-12-31 | (433.83M) | -244.8% |
| FY2022 | 2022-12-31 | (125.8M) | +16.3% |
| FY2021 | 2021-12-31 | (150.37M) | — |
Financing Cash Flow vs competitors
How QGEN compares with its peers on the latest reported figures
- QGEN's LTM Jun 2026 financing cash flow of $376.41M is the 4th largest of the 11 companies compared; the peer median is $53.39M.
- Its year-over-year change of +18.3% is the 4th highest of 11, against a peer median of -64.1%.
- Financing cash flow amounts to 17.9% of revenue for QGEN, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $8.32B | +240.6% | +4.8% | 32.5% | |
| LTM Sep 2026 | $985M | +118.3% | — | 2.1% | |
| LTM Jul 2026 | $503.44M | -67.2% | +8.9% | 17.3% | |
| LTM Jun 2026 | $376.41M | +18.3% | +12.5% | 17.9% | |
| LTM Jun 2026 | $164.27M | -32.1% | -55.5% | 78.7% | |
| LTM Jun 2026 | $121.1M | -66.0% | — | 4.7% | |
| LTM Sep 2026 | $108.53M | -62.1% | — | 8.8% | |
| LTM Jul 2026 | $95M | -80.6% | -19.5% | 1.3% | |
| LTM Jun 2026 | $35.1M | +205.1% | — | 1.0% | |
| LTM Jun 2026 | $11.79M | -85.9% | +4.5% | 1.5% | |
| LTM Jun 2026 | $2.54M | -129.5% | -24.5% | 0.4% | |
| Peer median (excluding QGEN) | $53.39M | -64.1% | -7.5% | 3.4% | |
Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 512.6M | 423.21M | 341.3M | 83.59M | 424.88M |
| Depreciation & Amortization | 214.93M | 208.4M | 205.34M | 203.27M | 193.75M |
| Deferred Income Tax | (5.29M) | (9.6M) | 10.73M | (23.04M) | (20.07M) |
| Stock-Based Compensation | 38.39M | 49.51M | 47.1M | 43.63M | 50.4M |
| Change in Working Capital | (130.01M) | (31.88M) | (186.96M) | 135.45M | (34.51M) |
| Accounts Receivables | (7.4M) | 15.45M | (55.12M) | 12.22M | (36.39M) |
| Inventory | (81.8M) | (61.95M) | (44.79M) | 87.76M | (848K) |
| Accounts Payables | (5.98M) | (1.76M) | (22.42M) | 1.45M | (8.42M) |
| Other Working Capital | (34.83M) | 16.37M | (64.64M) | 34.03M | 11.15M |
| Other Non-Cash Items | 8.38M | 75.63M | 41.94M | 230.65M | 39.88M |
| Operating Cash Flow | 639M | 715.26M | 459.46M | 673.55M | 654.33M |
| Capital Expenditures | (206.53M) | (149.34M) | (162.8M) | (167.17M) | (201.05M) |
| Acquisitions (Net) | (16.63M) | (63.65M) | (149.53M) | 0 | (291.23M) |
| Purchases of Investments | (400.3M) | (1.39B) | (979.32M) | (688.38M) | (371.82M) |
| Sales of Investments | 359.56M | 883.08M | 1.27B | 584.98M | 597.06M |
| Other Investing Activities | 61.47M | (9.77M) | (66.55M) | 21.35M | (32.16M) |
| Investing Cash Flow | (202.43M) | (726.76M) | (87.66M) | (249.23M) | (305.28M) |
| Debt Repayment | (41.35M) | (108.55M) | (436.76M) | (107.33M) | 208.15M |
| Common Stock Issued | 7.92M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (99.99M) | (25.36M) | (17.68M) | (292.1M) | (307.36M) |
| Dividends Paid | 0 | 0 | 0 | 0 | (54.24M) |
| Other Financing Activities | (16.95M) | 8.11M | 20.61M | (23.47M) | (25.53M) |
| Financing Cash Flow | (150.37M) | (125.8M) | (433.83M) | (422.9M) | (178.98M) |
| Effect of Forex Changes | (3.68M) | (12.55M) | (558K) | (5.96M) | 5.38M |
| Net Change in Cash | 282.53M | (149.85M) | (62.59M) | (4.53M) | 175.45M |
| Free Cash Flow | 432.47M | 565.93M | 296.65M | 506.38M | 453.28M |
Qiagen N.V.
NYSE:QGEN
Intrinsic Alpha fair value
Locked
Current Price
$49.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.